<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109456</url>
  </required_header>
  <id_info>
    <org_study_id>IN10018-004-01</org_study_id>
    <nct_id>NCT04109456</nct_id>
  </id_info>
  <brief_title>IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma</brief_title>
  <official_title>A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InxMed (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InxMed (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and&#xD;
      antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in&#xD;
      subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with metastatic uveal melanoma (UM) or with NRAS-mutant metastatic melanoma will be&#xD;
      enrolled.&#xD;
&#xD;
      IN10018 will be assessed firstly as monotherapy, and then in combination with cobimetinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The safety and tolerability of IN10018 monotherapy will be assessed firstly. Other dose levels may be explored if necessary.&#xD;
And then the safety and tolerability of IN10018 in combination with Cobimetinib will be evaluated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of IN10018 monotherapy</measure>
    <time_frame>The first 21-day cycle</time_frame>
    <description>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of IN10018 in combination with cobimetinib</measure>
    <time_frame>The first 28-day cycle</time_frame>
    <description>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : Cmax</measure>
    <time_frame>Cycle 1 and Cycle 3</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : AUC</measure>
    <time_frame>Cycle 1 and Cycle 3</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : tmax</measure>
    <time_frame>Cycle 1 and Cycle 3</time_frame>
    <description>Time to Cmax (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : t1/2</measure>
    <time_frame>Cycle 1 and Cycle 3</time_frame>
    <description>Elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : CL/F</measure>
    <time_frame>Cycle 1 and Cycle 3</time_frame>
    <description>apparent clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : Vd</measure>
    <time_frame>Cycle 1 and Cycle 3</time_frame>
    <description>Apparent volume of distribution(Vd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rates using RECiST1.1 criteria</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of participants with (complete response, partial response, stable disease, progressive disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate using RECiST1.1 criteria</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of subjects who have disease control (CR, PR or stable disease (SD))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>For subjects who demonstrate CR or PR, DOR is defined as the time from first evidence of CR or PR until PD or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS is defined as the time from the first day of study treatment to the first disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>OS is defined as the time from the first day of study treatment to death due to any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To explore potential predictive biomarkers</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the level of Phospho-FAK [Tyr 397]</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Part 1, Monotherapy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The safety and tolerability of IN10018 monotherapy will be assessed. Other dose levels may be explored if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Combination Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The safety and tolerability of IN10018 in combination with Cobimetinib will be assessed. Other dose levels may be explored if necessary.&#xD;
A modified 3+3 design will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN10018</intervention_name>
    <description>100 mg, orally once daily continuously</description>
    <arm_group_label>Part 1, Monotherapy Arm</arm_group_label>
    <arm_group_label>Part 2, Combination Arm</arm_group_label>
    <other_name>BI 853520</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>60mg , orally once daily from day 1 to day 21 in a 28-day cycle</description>
    <arm_group_label>Part 2, Combination Arm</arm_group_label>
    <other_name>Cotellic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic uveal melanoma or Metastatic&#xD;
             NRAS-mutant melanoma .&#xD;
&#xD;
          -  At least one measurable lesion can be accurately measured per RECIST 1.1 by&#xD;
             investigator.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Adequate organ system functions as defined in the protocol&#xD;
&#xD;
          -  A male subject must agree to use contraception as detailed in protocol during the&#xD;
             treatment period and through 30 days after the last dose of study treatment and must&#xD;
             refrain from donating sperm during this period.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is not pregnant, not breastfeeding.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has had major surgery or significant traumatic injury within 28 days prior to first&#xD;
             dose of study treatment, or anticipation of the need for major surgery during study&#xD;
             treatment.&#xD;
&#xD;
          -  Has received prior systemic anticancer therapy including investigational agents, such&#xD;
             as within 14 days or less than 5 half-lives (whichever is shorter) of chemotherapy or&#xD;
             targeted therapy, or within 28 days of immunotherapy, prior to first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Has received prior radiotherapy within 14 days prior to first dose of study treatment.&#xD;
&#xD;
          -  Has received prior treatment of any FAK inhibitor (Part 1&amp;2), or prior treatment of&#xD;
             any MEK inhibitor (Part 2 only).&#xD;
&#xD;
          -  Has a known previous or concurrent cancer that is distinct in primary site or&#xD;
             histology from current uveal melanoma within 3 years prior to first dose of study&#xD;
             treatment, except for curatively treated cancers such as cervical carcinoma in situ).&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  Has a history of major cardiovascular, cerebrovascular or thromboembolic diseases&#xD;
             within 6 months before first dose of study treatment, or has any of the abnormality&#xD;
             defined in protocol:&#xD;
&#xD;
          -  Part 2 only: Has history or current evidence of retinal pigmented epithelial&#xD;
             detachment, central serous retinopathy, or retinal vein occlusion in the unaffected&#xD;
             eye; or intraocular pressure &gt; 21 mmHg or uncontrolled glaucoma (irrespective of&#xD;
             intraocular pressure) in the unaffected eye.&#xD;
&#xD;
          -  Has known uncontrollable pleural effusion, pericardial effusion, or ascites requiring&#xD;
             repeated drainage prior to the first dose of study treatment.&#xD;
&#xD;
          -  Has malabsorption syndrome or inability to take oral drugs or Has clinically&#xD;
             significant gastrointestinal abnormalities.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to IN10018 and/or cobimetinib, or their ingredients.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy within 14 days prior to the first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Has known HIV/ active HBV/ active HCV infection.&#xD;
&#xD;
          -  subject is not suitable for participating this study based on the investigator's&#xD;
             judgement.&#xD;
&#xD;
          -  has used Strong CYP3A inhibitors/inducers or P-gp inhibitors within 14 days prior to&#xD;
             first dose of study treatment and during study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddie Xing, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>InxMed Shanghai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eddie Xing, Dr.</last_name>
    <phone>9495200786</phone>
    <email>eddie.xing@inxmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Feun, Dr.</last_name>
      <phone>305-243-4981</phone>
      <email>lfeun@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Sullivan, MD</last_name>
      <phone>617-724-4000</phone>
      <email>RSULLIVAN7@PARTNERS.ORG</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rizwan Haq, PhD.</last_name>
      <phone>617-632-5055</phone>
      <email>Rizwan_haq@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachard Carvajal, Dr.</last_name>
      <email>rdc2150@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sapna Patel</last_name>
      <phone>713-792-2921</phone>
      <email>melanoma@mdanderson.org.org</email>
    </contact>
    <investigator>
      <last_name>Sapna Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveal</keyword>
  <keyword>NRAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

